Fig. 1. Patient distribution. Of the 709 deceased donor kidney transplantation (KT) recipients included in this study, 579 had panel-reactive antibody (PRA) less than 50%, and 130 had PRA 50% or more. Of the deceased-donor kidney transplantation (DDKT) recipients with a PRA of less than 50%, 470 did not develop delayed graft function (DGF), and 109 developed DGF. Among DDKT recipients with a PRA of 50% or more, 103 did not develop DGF and 27 developed DGF.
